イスタンブールで最高の悪性黒色腫医師 - トップ31名の医師

900件以上の黒色腫処置を実施 – ビュレント・カラゴズ医師は、アナドル医療センターにて免疫療法および分子標的療法を専門としています。

• 33年の経験 の腫瘍内科診療経験
• イスタンブール・オカン大学医学部 教授
• トルコ腫瘍内科学会 会員
• がん研究分野における学術論文40件以上を発表

Eda Tanrikulu教授は転移性悪性黒色腫を専門とし、アナドル医療センターにおけるがん症例評価においてリーダーシップを発揮しています。

• 腫瘍内科の専門医資格を有し、21年の経験以上の臨床経験を持つ
• トルコ腫瘍内科専門医試験において全国3位を獲得
• 腫瘍学における国際臨床研究を主導
• ハイダルパシャ・ヌムネ病院にて主任研究員を歴任

Mustafa Solak氏は、ヒサール・インターコンチネンタル病院にて、黒色腫を含む1,100件以上のがん治療を実施しています。

• 腫瘍学における20年の経験の経験
• ハジェテペ大学がん研究所にて研修
• テキサス大学MDアンダーソンがんセンターに勤務
• 黒色腫を含むさまざまながんを専門とする

Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.

Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

シナン・カラアスラン博士は、乳がん、大腸がん、泌尿生殖器系がんの管理において最高の腫瘍医の一人です。

職務経験

• 2014年から — アナドル医療センターの腫瘍内科医
• 2012-2014 — メディカルパークホスピタルの腫瘍内科医
• 2011-2012 — コジャエリ・デリンセ教育研究病院の腫瘍内科医
• 2010-2011 — エルズルム地域教育研究病院の腫瘍内科医
• 2009-2010 — トルコ武装軍、ギュルハネ軍事医科大学での軍務中の腫瘍内科学の専門家
• 2006-2009 — チェラッパシャ医科大学腫瘍内科学科での腫瘍内科学フェロー
• 2003-2006 — バイランパシャ国立病院の内科専門医
• 1997-2003 — ハセキ教育研究病院の内科研修生兼内科専門医。

教育

• 1997 — イスタンブール大学イスタンブール医科大学 — 一般医学の学位
• 2002 — ハセキ研修病院 — 内科の専門
• 2009 — イスタンブール大学、チェラッパシャ医科大学 — 腫瘍内科の専門。

所属

• トルコ医学会
• トルコ腫瘍医学会
• トルコ肺がん学会。

900件以上の治療実績 – セルカン・ケシキン医師は、進行期黒色腫治療を専門とする高評価の腫瘍内科医です。

• トルコ腫瘍内科専門医資格試験で第1位を獲得
• 国際腫瘍学専門誌に42本の論文を発表
• 世界有数の腫瘍学学会であるASCOおよびESMOの会員
• 25年の経験 の複雑ながん症例の診療経験
• 化学療法、免疫療法、および分子標的療法の専門家

イェシム・ユルドゥルム教授は、がん免疫療法および分子標的治療を専門とし、80を超える国際学術論文および共著書籍を有しています。

• 欧州臨床腫瘍学会（ESMO）会員
• マウント・バーノン・キャンサーセンターにてメラノーマおよび腎臓がんクリニックの研修を修了
• イスタンブール・ハリチ大学教授
• アナドル医療センターにて22年の経験の診療経験

Şeref Kömürcü教授は、ECFMGおよびESMO認定の医療および乳腺腫瘍学者であり、トルコを拠点に20年以上の実践経験を持っています。硬癌、乳癌、大腸癌、肺癌の治療を専門としています。

職歴

• 2016年から — アナドル医療センターでの医療腫瘍学専門家

学歴

• 1986年 — ギュルハネ軍医学校 — 一般医学の学位
• 1993年 — ギュルハネ軍医学校 — 内科専門
• 1993年 — ECFMG（米国）証明書取得
• 1996年 — ギュルハネ軍医学校 — 医療腫瘍学専門
• 1999年 — ESMO医療腫瘍学証明書取得（ヨーロッパ）。

教育活動

• 2011-2016年 — ギュルハネ軍医学校の医療腫瘍学部で教授
• 1999-2011年 — ギュルハネ軍医学校の医療腫瘍学部で准教授。

受賞

• 2003年 — GATA教育および教育の成功賞
• 2009年 — GATA卓越したサービス賞。

科学活動

癌管理に関する110を超える論文を書いています。

会員

• アメリカ臨床腫瘍学会
• ヨーロッパ医療腫瘍学会
• 多国籍癌支持療法協会
• トルコ腫瘍グループ
• トルコ医療腫瘍機構
• 肺癌機構
• 医療コミュニケーション機構
• 乳房疾患協会。

この医師は、35年以上の経験を持つリーディングプラスチックサージャンであり、がん後、火傷、皮膚腫瘍の手術、成人および子供のための手および顎顔面手術を専門としています。<\/p>

彼は、Anadolu Medical Center、Mevki Military Hospital、GATA Haydarpaşa Training Hospital、Brooke Army Medical Center、Çorlu Military Hospitalなどの著名な機関で働いてきました。<\/p>

彼はイスタンブール大学医学部から一般医学の学位を取得し、アンカラGATA医科大学でプラスチックおよび再建外科を専門とし、The University of Texas MD Anderson Cancer Centerからフェローシップを受けました。<\/p>

この医師は60以上の論文を発表し、100以上の会議に参加しており、いくつかの国際外科学会のメンバーです。<\/p>

プロフェッサー ネジデット・ユシュケントは、アンカラ大学医学部を卒業しました。彼はアンカラGATA医学校で内科医学のレジデンシー研修を修了しました。彼はアメリカのテキサス州ダラスで医療用腫瘍学および血液学の臨床フェローシップ研修を行いました。トルコで最初の移植を実施した骨髄移植チームに参加しました。異なる時期に、彼はロンドンのウェストミンスター病院 チャリングクロス、ハマースミス、ロイヤル フリー、ユニバーシティ カレッジ 病院で長期間の客員講師を務め、スイスのバーゼル カントン病院でも講義しました。欧州医学腫瘍学会（ESMO）によって主催された試験に合格し、彼はヨーロッパ医学腫瘍学証明書を取得しました。トルコ医学腫瘍学会の7人の創設会員の1人として、プロフェッサー ユシュケントはトルコ腫瘍学グループ（TOG）の創設者でもありました。

学歴

大学 

アンカラ大学医学部, アンカラ 1971 

専門教育 

GATA 医学校, アンカラ 1979 
 

ワドレー分子医学研究所, グランビル・モートンがん病院, 医療用腫瘍学および血液学のサブスペシャリティ, 1982

助教

GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1984 

准教授 

GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1989 

教授 

GATA, 医療用腫瘍学および血液学クリニック, イスタンブール 2001

専門分野

• 乳がん
• 胃腸がん
• 肺がん
• リンパ腫
• 骨髄腫
  
  所属機関
  
  トルコ医学腫瘍学会
• トルコ血液学会
• 肺がん学会
• 免疫腫瘍学会
• 神経腫瘍学会
• 乳がん学会
• イスタンブール胃腸がんグループ
• イスタンブールリンパ腫グループ
• イスタンブール骨髄腫グループ
• 欧州医学腫瘍学会（ESMO）
• 米国臨床腫瘍学会

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

この医師は、トルコのいくつかの著名な病院で豊富な経験を持つベテランの医療腫瘍学者であり、2019年からMemorial Bahçelievler Hospitalに勤務しています。Cerrahpasa Faculty of Medicineで医学の学位を取得し、Sisli Etfal Training and Research Hospitalで内科のレジデンシーを修了し、Istanbul Bilim Universityで医療腫瘍学のレジデンシーを修了しました。2016年に准教授の地位を達成し、医療腫瘍学の分野で20以上の論文と10の書籍の章を執筆しています。

2012年にトルコ医療腫瘍学会から腫瘍研究賞を受賞し、ヨーロッパ医療腫瘍学会を含む複数の専門学会の積極的なメンバーです。

Dermatologist

この医師は、乳がん、肺がん、消化器系がんの治療を専門とする腫瘍学者です。現在、医師はIstinye Liv University Hospitalで診療を行っています。<\/p>

多くの著名な機関でのキャリアを持ち、医師はMalatya State Hospitalで内科専門医として、Ankara Oncology Clinicで医師として、Erzurum Regional Training and Research Hospitalの腫瘍学部門のメンバーとして勤務してきました。<\/p>

医師はSelcuk Universityの医学部を卒業し、2016年に准教授の称号を取得しました。<\/p>

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)